Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.45 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24557310 | 0.90 | PIK3CD (0.46) | ABL1GSK3BMAP4K1PIK3CDPIM1 | |
| SCHEMBL24557247 | 0.88 | ABL1 (0.48) | ABL1GSK3BMAP4K1NPC1RAB9A | |
| SCHEMBL29638382 | 0.86 | ABL1 (0.53) | ABL1GSK3BNPC1RAB9A | |
| SCHEMBL24557299 | 0.86 | MAP4K1 (0.46) | ABL1MAP4K1 | |
| SCHEMBL29638461 | 0.86 | DEGS1 (0.51) | ABL1MAP4K1DEGS1 | |
| SCHEMBL29638459 | 0.86 | ABL1 (0.55) | ABL1GSK3B | |
| SCHEMBL29638419 | 0.85 | TRPV1 (0.50) | ABL1 | |
| SCHEMBL24557316 | 0.84 | ABL1 (0.47) | ABL1MAP4K1NPC1RAB9A | |
| SCHEMBL29638346 | 0.84 | ABL1 (0.47) | ABL1MAP4K1NPC1RAB9A | |
| SCHEMBL29638359 | 0.84 | KDR (0.49) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124440-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-04-18 | — | — | US | disclosed |
| WO-2022136914-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124440-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ABL1 13/4885GSK3B 87/4885KCNH2 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.